Compare IAC/Interactivecorp (PPLI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs TG Therapeutics Inc — how do they compare? IAC/Interactivecorp trades at $40.89 (market cap $3.05B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.7× IAC/Interactivecorp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and TG Therapeutics Inc for 16 Days on average.
| PPLI | TGTX | |
|---|---|---|
Market Cap | $3.05B | $8.16B |
Volume | 931,019 | 1,735,121 |
Sector | Media | Health |
52-Week High | $47.62 | $59.06 |
52-Week Low | $31.52 | $26.94 |
Typical Hold Time | 79 Days | 16 Days |
Enterprise Value | $3.53B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.93, up 0.84% today, with a bullish technical signal from moving averages and strong analyst support (71% buy ratings). Recent news highlights potential M&A interest from MGM Resorts, driving volatility. Financially, the company shows mixed results with a negative net income in 2025 but improved revenue stability and attractive valuation ratios like a P/E of 6.92 and P/B of 0.6.
The outlook is cautiously optimistic due to takeover speculation and low valuation, but risks include inconsistent earnings, high debt, and industry challenges. Further upside depends on successful strategic moves or M&A realization, while failure to improve profitability could pressure the stock.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
